Tango Therapeutics, Inc. (TNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.52-1.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TNGX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on progressing vopimetostat in combination with RAS(ON) inhibitors through Phase 1/2 and into Phase 3 development for MTAP-deleted pancreatic cancer and other indications.
Stated as a priority in 2 of last 2 quarters. Initial Phase 1/2 data in 2026-Q2 showed vopimetostat plus daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival in MTAP-deleted pancreatic cancer. CEO reiterated plans to rapidly advance this combination into Phase 3 development. The trajectory is delivering with clinical data supporting advancement.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“CEO: 'Initial Phase 1/2 data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate... moving rapidly into Phase 3 development.'”
“CEO: 'We continue to work diligently to advance vopimetostat towards pivotal development in pancreatic cancer...'”
Continue to control operating expenses and manage net losses while advancing clinical programs and preparing for commercialization.
Stated as a priority in 2 of last 2 quarters. Cash position increased significantly from $380 million in 2026-Q1 to $1.0 billion in 2026-Q2, supporting the operating plan. However, net loss increased from $45.5 million to $55.3 million over the same period. Management emphasizes runway sufficiency while managing losses, indicating mixed progress.
“CEO: 'Cash position of $1.0 billion as of June 30, 2026... funding current operating plan.'”
“CEO: 'Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points.'”
Raise capital through equity offerings and other means to support clinical development and commercialization efforts.
Newly stated in 2026-Q2. The company announced an underwriting agreement to offer 18,166,667 shares to raise capital. This capital raise aligns with management's stated need to support ongoing clinical development and commercialization preparation. No prior quarters mention this, so progress is initial.
“On June 9, 2026, entered underwriting agreement for offering of 18,166,667 shares of common stock.”
Over the trailing year it converted 0.98x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
14 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.